A
Allarity Therapeutics, Inc. (ALLR)
NCM – Real vaqt narxi. Valyuta: USD
1.52
-0.16 (-9.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.51
-0.01 (-0.65%)
Bozordan keyin: May 12, 2026, 7:31 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.52
-0.16 (-9.52%)
Yopilishda: May 12, 2026, 4:00 PM EDT
1.51
-0.01 (-0.65%)
Bozordan keyin: May 12, 2026, 7:31 PM EDT
Allarity Therapeutics, Inc., klinik bosqichdagi aniq tibbiyot farmatsevtika kompaniyasi bo'lib, Daniya va Qo'shma Shtatlardagi tibbiy ehtiyojlari qondirilmagan bemorlar uchun saratonga qarshi davolash vositalarini ishlab chiqishga qaratilgan. Kompaniya o'zining patentlangan dorilarga javob berish prognozlovchi (DRP) texnologiyasi tomonidan ishlab chiqarilgan dorilarga xos bo'lgan hamrohlik diagnostik vositalaridan foydalangan holda saratonni shaxsiylashtirilgan davolash uchun dori vositalarini ishlab chiqadi. Uning yetakchi dori nomzodi stenoparib, pol-ADP-riboza polimeraza (PARP1/2) ning ikki tomonlama ingibitori bo'lib, u rivojlangan va takroriy tuxumdon saratoni bilan og'rigan bemorlar uchun 2-bosqichli klinik sinovdan o'tmoqda. Shuningdek, u stenoparibni temozolomid bilan birgalikda ishlab chiqmoqda, bu PARP va WNT ingibitori bo'lib, u DNK-alkillovchi kimyoterapiya vositasi bilan birgalikda, takrorlangan mayda hujayrali o'pka saratoni bilan og'rigan bemorlar uchun 2-bosqichli klinik sinovdan o'tmoqda; va stenoparib-DRP, stenoparib bilan davolash uchun bemorlarni tanlash uchun ishlatiladigan hamrohlik diagnostika mahsuloti. Allarity Therapeutics, Inc. Tarpon Springs, Florida shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jeremy R. Graff Ph.D. | President & Chief Development Officer |
| Dr. Jose L. Iglesias M.D. | Consultant Chief Medical Officer |
| Dr. Steen Meier Knudsen Ph.D. | Founder & Chief Scientific Officer |
| Mr. Jeffrey S. Ervin M.B.A. | Chief Financial Officer |
| Mr. Thomas H. Jensen | Founder, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-08 | 8-K | ea0289893-8k_allarity.htm |
| 2026-05-06 | 8-K | ea0289243-8k_allarity.htm |
| 2026-04-30 | DEF 14A | ea0287703-01.htm |
| 2026-04-28 | 8-K | ea0287908-8k_allarity.htm |
| 2026-04-24 | S-3/A | ea0287396-s3a1_allarity.htm |
| 2026-04-22 | 8-K | ea0287156-8k_allarity.htm |
| 2026-04-10 | PRE 14A | ea0285611-pre14a_allarity.htm |
| 2026-04-01 | 8-K | ea0279571-8k_allarity.htm |
| 2026-03-30 | 10-K | allr20251231_10k.htm |
| 2026-03-09 | 8-K | ea0280539-8k_allarity.htm |